The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2021 | Novel targets and dual-targeting approaches in myeloma
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, talks on novel targets with promise in the multiple myeloma field. While BCMA represents a well-established, effective target for myeloma therapeutics, emerging evidence is demonstrating the potential for development of resistance in some patients. Prof. Martin discusses emerging targets under investigation, including GPRC5D and FcRH5. SLMAF7 and CD38 may also be useful in the development of dual-targeted therapies. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
